Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|April 23, 2015
Sartorius Unveils New Concept for Packaging Pipette Tips
Author(s)Pharmaceutical Technology Editors
FlexiBulk tip packs save space and effort in the laboratory
Sartorius, laboratory equipment supplier for the pharmaceutical industry, announced the introduction of a new concept of packaging pipette tips, FlexiBulk. The new orderly tip arrangement saves laboratory space and enables quick attaching to pipettes or convenient loading of tips onto tip racks.
According to Sartorius, the stackable FlexiBulk boxes take up to 40% less space and cut packaging waste by nearly 50% compared with conventional bulk tip packages. The new packaging concept also helps reduce transportation costs and laboratories’ carbon footprint.
FlexiBulk tips come with certification that they are free of RNase, DNase, and endotoxins. The tips are produced and packaged under ISO class 8 cleanroom conditions. The manufacturing process is fully automated, thus eliminating contamination.
The lid on the FlexiBulk box provides an airtight seal, ensuring complete cleanliness of the tips during transportation and storage. The lid is easy to open and is reclosable.
The compact boxes are made of recyclable but durable polyethylene material (PET). They can be stacked without any outer cardboard box needed.
The tips in FlexiBulk packs have the same high quality as other Sartorius Optifit tips available in racks and refill packages. They perfectly fit Sartorius pipettes, such as Picus, Picus NxT, eLINE, mLINE, and Proline Plus, as well as most other pipette brands, providing an air-tight seal. The FlexiBulk packs cover a tip volume range from 0.5 µl to 1,200 µl.
Source:
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
What the Olanzapine Depot Approval Means for CMC Teams
5